Efficacy and Safety of Trastuzumab Combined with Pertuzumab for Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer: A Meta-Analysis Study of Randomized Control Trials

Author:

Gao Qingdong1ORCID,Duan Xufang2

Affiliation:

1. Pharmacy Department, Jiamusi Hospital of Traditional Chinese Medicine, Jiamusi, Heilongjiang 154002, China

2. Pharmacy Department, Jiamusi Xiangyang District People’s Hospital, Jiamusi, Heilongjiang 154003, China

Abstract

Objective. This systematic review was aimed to evaluate the efficacy and safety of trastuzumab in combination with pertuzumab for human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC). Methods. A comprehensive search of PubMed, Web of Science, Embase, China National Knowledge Internet, and Wanfang databases was conducted. All randomized controlled trials on trastuzumab in combination with pertuzumab for HER2-positive BC from the time of database construction to October 2022 were included. A meta-analysis of the included literature was performed using STATA 17.0 software. Results. A total of 8 studies were included, involving a total of 7628 patients, including 3814 patients in the treatment group and 3814 patients in the control groups. The results of the meta-analysis showed that the median progression-free survival was much shorter in the treatment group (trastuzumab combined with pertuzumab) than in the control group (placebo) (OR = 0.656, 95% CI (0.581, 0.741), P  < 0.001) and that patients in the treatment group experienced significantly more cases of diarrhea than those in the control group (OR = 2.429, 95% CI (2.065, 2.856), P  < 0.001) while experiencing significantly less cases of constipation (OR = 0.641, 95% CI (0.473, 0.869), P  = 0.004). Notably, the incidence of nausea and vomiting did not differ significantly between the two groups. In addition, there was no significant difference between the two groups in the incidence of systemic adverse effects such as neutropenia, fatigue, myalgia, and cardiac disease ( P  > 0.05). However, the treatment group had a much higher incidence of rash than the control group (OR = 1.915, 95% CI (1.505, 2.437), P  < 0.001). The risk of serious adverse reactions was markedly higher in patients in the treatment group than that in the control group (OR = 1.342, 95% CI (1.206, 1.494), P  < 0.001). Conclusion. The combination of trastuzumab and pertuzumab was not effective in improving the intermediate progression-free survival of patients. However, adverse effects, including diarrhea and rash, are the limiting factors for the current promotion of this combination method.

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3